<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Vaccines (Basel)</journal-id><journal-id journal-id-type="iso-abbrev">Vaccines (Basel)</journal-id><journal-id journal-id-type="publisher-id">vaccines</journal-id><journal-title-group><journal-title>Vaccines</journal-title></journal-title-group><issn pub-type="epub">2076-393X</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC11680344</article-id><article-id pub-id-type="doi">10.3390/vaccines12121359</article-id><article-id pub-id-type="publisher-id">vaccines-12-01359</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Effects of Baseline Blood Zinc Levels on the Humoral Immune Response After COVID-19 mRNA Vaccination: A Prospective Study in a Japanese Population</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-3516-4833</contrib-id><name><surname>Ashenagar</surname><given-names>Mohammad Said</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role><xref rid="af1-vaccines-12-01359" ref-type="aff">1</xref><xref rid="c1-vaccines-12-01359" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-8708-3237</contrib-id><name><surname>Hara</surname><given-names>Megumi</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role><xref rid="af2-vaccines-12-01359" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Yamada</surname><given-names>Gouki</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="af3-vaccines-12-01359" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-1504-7795</contrib-id><name><surname>Tokiya</surname><given-names>Mikiko</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="af1-vaccines-12-01359" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-8445-4071</contrib-id><name><surname>Matsumoto</surname><given-names>Akiko</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><xref rid="af1-vaccines-12-01359" ref-type="aff">1</xref><xref rid="c1-vaccines-12-01359" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Georgopoulos</surname><given-names>Apostolos P.</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-vaccines-12-01359"><label>1</label>Department of Social and Environmental Medicine, Faculty of Medicine, Saga University, 5-1-1 Nabeshima, Saga 849-8501, Japan; <email>sx4932@cc.saga-u.ac.jp</email></aff><aff id="af2-vaccines-12-01359"><label>2</label>Department of Preventive Medicine, Faculty of Medicine, Saga University, 5-1-1 Nabeshima, Saga 849-8501, Japan; <email>harameg@cc.saga-u.ac.jp</email></aff><aff id="af3-vaccines-12-01359"><label>3</label>The United Graduate School of Agricultural Sciences, Kagoshima University, 1-21-24 Korimoto, Kagoshima 890-0065, Japan; <email>k6658152@kadai.jp</email></aff><author-notes><corresp id="c1-vaccines-12-01359"><label>*</label>Correspondence: <email>sx5080@cc.saga-u.ac.jp</email> (M.S.A.); <email>matsumoa@cc.saga-u.ac.jp</email> (A.M.)</corresp></author-notes><pub-date pub-type="epub"><day>30</day><month>11</month><year>2024</year></pub-date><pub-date pub-type="collection"><month>12</month><year>2024</year></pub-date><volume>12</volume><issue>12</issue><elocation-id>1359</elocation-id><history><date date-type="received"><day>18</day><month>10</month><year>2024</year></date><date date-type="rev-recd"><day>26</day><month>11</month><year>2024</year></date><date date-type="accepted"><day>29</day><month>11</month><year>2024</year></date></history><permissions><copyright-statement>&#x000a9; 2024 by the authors.</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>Background/Objectives: Although the protective effects of zinc against COVID-19 are documented, its impact on COVID-19 vaccine immunogenicity remains unknown. Methods: We conducted a prospective study involving a cohort of 79 Japanese individuals (aged 21&#x02013;56 years; comprising three subcohorts) and measured their serum zinc levels pre-vaccination and anti-SARS-CoV-2 IgM/IgG levels pre- and post-vaccination over 4 months. Results: Serum zinc concentrations ranged between 74&#x02013;140 and 64&#x02013;113 &#x003bc;g/dL in male and female individuals, respectively, with one male and 11 female participants exhibiting subclinical zinc deficiency (60&#x02013;80 &#x003bc;g/dL). Mixed models for antibody titers, accounting for the subcohorts, repeat measurements, and covariates (e.g., vaccine type, sex, age, height, steroid use, medical history, smoking and drinking habits, perceived stress, and sleep disturbances) showed positive effects of zinc on IgM (<italic toggle="yes">p</italic> = 0.012) and IgG (<italic toggle="yes">p</italic> = 0.013) in 45 female individuals with 255 observations. However, a similar association was not found in the 34 male participants with 162 observations. This discrepancy may be attributed to one participant being included in the subcohort with frequent repeat measurements (10 repeats in 4 months). COVID-19 mRNA vaccine immunogenicity was enhanced in the participants with high baseline blood zinc levels within the reference range. Conclusions: Our findings underscore the relevance of maintaining adequate zinc levels before vaccination, which can be achieved through a balanced diet and healthy lifestyle choices.</p></abstract><kwd-group><kwd>humoral immune response</kwd><kwd>immunogenicity</kwd><kwd>SARS-CoV-2</kwd><kwd>vaccination</kwd><kwd>zinc</kwd></kwd-group><funding-group><award-group><funding-source>Ministry of Health, Labour and Welfare, Japan</funding-source><funding-source>Japanese Ministry of Education, Culture, Sports, Science and Technology</funding-source><award-id>R2-SHINKOGYOSEI-SHITEI-003</award-id><award-id>20HA200</award-id><award-id>24HA2007</award-id></award-group><funding-statement>This study was funded by a research grant for Research on Emerging and Re-emerging Infectious Diseases, Health, and Labour Science Research Grants from the Ministry of Health, Labour and Welfare, Japan (R2-SHINKOGYOSEI-SHITEI-003, 20HA200, and 24HA2007) of the Japanese Ministry of Education, Culture, Sports, Science and Technology. The funding organizations did not influence the study design, data collection, analysis, interpretation, or writing of the manuscript.</funding-statement></funding-group></article-meta></front><body><sec sec-type="intro" id="sec1-vaccines-12-01359"><title>1. Introduction</title><p>COVID-19 is a global health threat, highlighting the crucial role of the immune system in combating the SARS-CoV-2 infection. Recognized risk factors for severe infection include age, sex, and insufficient levels of micronutrients, including zinc [<xref rid="B1-vaccines-12-01359" ref-type="bibr">1</xref>,<xref rid="B2-vaccines-12-01359" ref-type="bibr">2</xref>,<xref rid="B3-vaccines-12-01359" ref-type="bibr">3</xref>,<xref rid="B4-vaccines-12-01359" ref-type="bibr">4</xref>]. Zinc, an essential trace element, plays a vital role in supporting both innate and adaptive immunity [<xref rid="B5-vaccines-12-01359" ref-type="bibr">5</xref>,<xref rid="B6-vaccines-12-01359" ref-type="bibr">6</xref>,<xref rid="B7-vaccines-12-01359" ref-type="bibr">7</xref>,<xref rid="B8-vaccines-12-01359" ref-type="bibr">8</xref>]. For instance, zinc is involved in the maturation of dendritic cells, the activation of mast cells, and T cell maturation. The disruption of zinc homeostasis can profoundly affect the adaptive immune response [<xref rid="B9-vaccines-12-01359" ref-type="bibr">9</xref>], potentially impairing antibody production [<xref rid="B10-vaccines-12-01359" ref-type="bibr">10</xref>], which crucially affects the humoral immune response, also known as the antibody-mediated immune response [<xref rid="B11-vaccines-12-01359" ref-type="bibr">11</xref>]. Given its crucial role in immune function, it is essential to investigate the association between baseline zinc levels and vaccine immunogenicity.</p><p>According to an observation of elderly individuals in nursing homes in the United States, normal baseline concentrations of blood zinc have been linked to lower overall mortality rates compared with low levels of zinc [<xref rid="B12-vaccines-12-01359" ref-type="bibr">12</xref>]. Several studies have reported low serum zinc levels in patients with COVID-19, which are associated with severe disease, death risk, and poor clinical outcomes [<xref rid="B13-vaccines-12-01359" ref-type="bibr">13</xref>,<xref rid="B14-vaccines-12-01359" ref-type="bibr">14</xref>,<xref rid="B15-vaccines-12-01359" ref-type="bibr">15</xref>]. Moreover, other studies have suggested that zinc supplementation could contribute to an additional defense against the illness [<xref rid="B16-vaccines-12-01359" ref-type="bibr">16</xref>,<xref rid="B17-vaccines-12-01359" ref-type="bibr">17</xref>,<xref rid="B18-vaccines-12-01359" ref-type="bibr">18</xref>], potentially by lowering the viral load and enhancing the immunity of patients with COVID-19. However, the association between the baseline levels of serum zinc and post-vaccination antibody titers has been scarcely studied. In an observational study of healthcare workers in Germany with a moderate level of baseline zinc who received two doses of an anti-SARS-CoV-2 vaccine (BNT162B2), the total serum zinc levels and supplementation showed no significant associations [<xref rid="B19-vaccines-12-01359" ref-type="bibr">19</xref>]. We believe that the results are inconclusive due to limitations, such as the small number of observation points, participants&#x02019; ethnicity, and confounding factors, such as psychological stress, sleep deprivation, and physical exercise, which could affect the zinc levels [<xref rid="B20-vaccines-12-01359" ref-type="bibr">20</xref>] and immune system function. Therefore, we performed a prospective study in a Japanese general population, measuring the serum zinc levels prior to vaccination and tracking anti-SARS-CoV-2 IgM and IgG levels before and for 4 months following vaccination. Our aim was to examine how baseline blood zinc levels affect the humoral immune response following COVID-19 mRNA vaccination.</p></sec><sec id="sec2-vaccines-12-01359"><title>2. Materials and Methods</title><p>This study was approved by the Ethics Committee for Clinical Research (approval number: R2&#x02013;44; date of approval: 25 March 2021, R3&#x02013;9; date of approval: 28 April 2021, R3&#x02013;39; date of approval: 24 November 2021) and the Human Genome/Gene Research Ethics Committee of Saga University (approval number: R2&#x02013;24; date of approval: 25 March 2021, R3&#x02013;4; date of approval: 28 April 2021). Written informed consent was obtained from all participants prior to any study-related procedures.</p><sec sec-type="subjects" id="sec2dot1-vaccines-12-01359"><title>2.1. Study Design and Participants</title><p>A total of 79 participants, comprising 11 healthcare workers, 68 students, and employees from hospitals and a university in Saga Prefecture, were enrolled in this study. Participants received either two doses of BNT162b2 (Pfizer Inc., New York, NY, USA/BioNTech SE, Mainz, Germany) at a dose of 30 &#x000b5;g (N = 53) or mRNA-1273 (Moderna Inc., Cambridge, MA, USA/Takeda Pharmaceutical Co., Ltd., Tokyo, Japan) at a dose of 100 &#x000b5;g (N = 26) (<xref rid="vaccines-12-01359-f001" ref-type="fig">Figure 1</xref>). The total number of observations was 255 for 45 female and 162 for 34 male individuals. The first and second doses of BNT162b2 were administered between April and May 2021, with a 21-day interval between doses. The first and second doses of Moderna&#x02019;s mRNA-1273 were administered in August 2021, with a 28-day interval between doses. None of the participants had a history of COVID-19 prior to vaccination. Blood samples were collected from all participants before the first vaccination (Week 0) and at various intervals up to Week 12 after the second vaccination. This included healthcare workers (Subcohort 1), university students (Subcohort 2), and university employees and students (Subcohort 3).</p></sec><sec id="sec2dot2-vaccines-12-01359"><title>2.2. Laboratory Testing</title><p>Serum samples were processed on the day of blood collection and subsequently stored at &#x02212;80 &#x000b0;C for later analysis. To quantify the levels of three types of anti-SARS-CoV-2 antibodies&#x02014;anti-spike protein (S1) IgG, anti-S1 IgM, and anti-nucleocapsid protein (N) IgG&#x02014;a high-sensitivity chemiluminescent enzyme immunoassay (CLEIA) platform (Sysmex Co., Kobe, Japan) was utilized [<xref rid="B21-vaccines-12-01359" ref-type="bibr">21</xref>]. The antibody concentrations were expressed as binding antibody units per milliliter (BAU/mL) for anti-S1 IgG and Sysmex units per milliliter (SU/mL) for both anti-S1 IgM and anti-N IgG. The BAU measurements were standardized based on the WHO International Standards.</p></sec><sec id="sec2dot3-vaccines-12-01359"><title>2.3. Self-Administered Questionnaire</title><p>Data were collected using a self-administered questionnaire, which included details of participants&#x02019; sex, age, height, weight, smoking habits, alcohol consumption, exercise routines, perceived stress, sleep disturbances, and medical history. Smoking behaviors were reported as unchanged over the past year. Alcohol intake was estimated based on the amount consumed in the preceding six months, adjusted for a 60 kg body weight, and categorized into four levels: less than 1 g/day, 1&#x02013;20 g/day, and 20 g/day or more. Exercise routines were evaluated through the question, &#x0201c;Do you typically engage in physical activity?&#x0201d; with responses categorized as: no regular activity, less than once per week, 1&#x02013;3 times per week, or more than three times per week. Stress levels were rated on a five-point scale, with options ranging from none (0) to yes, frequently (4). Sleep disturbance was classified as &#x0201c;yes&#x0201d; for positive indications and &#x0201c;no&#x0201d; for no indications. Participants receiving steroids at the time of the study were classified as &#x0201c;yes&#x0201d; for steroid use, while those who had not used steroids within the preceding 3 years were considered as &#x0201c;no.&#x0201d; Dyslipidemia was similarly categorized: participants with concurrent dyslipidemia were marked as &#x0201c;yes&#x0201d;, while those without a history of dyslipidemia in the previous three years were marked as &#x0201c;no&#x0201d;.</p></sec><sec id="sec2dot4-vaccines-12-01359"><title>2.4. Statistical Analyses</title><p>Statistical analyses were performed using SAS 9.4 TS Level 1M5 for Windows (SAS Institute, Cary, NC, USA) with an alpha value of 0.05. The primary outcomes, anti-S1-IgG (BAU/mL) and anti-S1-IgM (SU/mL) levels, along with the serum zinc level (&#x003bc;g/dL) as the primary explanatory variable, were log-transformed to achieve an approximate normal distribution. Male and female individuals were examined separately for the following reasons: (1) the estimation was possible for the whole observation period for 45 female individuals (255 observation points), while data for 34 male participants (162 observation points) were non-estimable at 1&#x02013;3 weeks after the second dose; and (2) there was a significant difference in the zinc levels according to sex (<xref rid="vaccines-12-01359-f002" ref-type="fig">Figure 2</xref>).</p><sec id="sec2dot4dot1-vaccines-12-01359"><title>2.4.1. Covariates</title><p>The analysis incorporated several covariates alongside sex, age, vaccine type, and weeks post-vaccination. These included height, smoking habits, alcohol consumption, exercise frequency, perceived stress, sleep issues, steroid use, and the presence of dyslipidemia. Previous research has identified these factors as being linked to variations in vaccine effectiveness, immune response, and zinc levels [<xref rid="B22-vaccines-12-01359" ref-type="bibr">22</xref>,<xref rid="B23-vaccines-12-01359" ref-type="bibr">23</xref>,<xref rid="B24-vaccines-12-01359" ref-type="bibr">24</xref>,<xref rid="B25-vaccines-12-01359" ref-type="bibr">25</xref>,<xref rid="B26-vaccines-12-01359" ref-type="bibr">26</xref>,<xref rid="B27-vaccines-12-01359" ref-type="bibr">27</xref>,<xref rid="B28-vaccines-12-01359" ref-type="bibr">28</xref>,<xref rid="B29-vaccines-12-01359" ref-type="bibr">29</xref>].</p></sec><sec id="sec2dot4dot2-vaccines-12-01359"><title>2.4.2. Mixed Model</title><p>Mixed model analysis was conducted to estimate log-transformed antibody titers, accounting for subcohorts, repeat measurements, and covariates in three models. Model 1 included the effects of the post-vaccination week, vaccine type, age, and zinc levels. Model 2 included lifestyle habits and current medical history factors, such as body height, steroid use, dyslipidemia, allergic disease, exercise habits, cigarette smoking, ethanol intake, perceived stress, and sleep disturbance.</p></sec><sec id="sec2dot4dot3-vaccines-12-01359"><title>2.4.3. Least Squares Geometric Means</title><p>The non-linear dose&#x02013;response relationships between zinc, anti-S1-IgG, and anti-S1-IgM are depicted as least-squares geometric means and standard errors for the categorized zinc levels. Anti-S1 IgG and IgM levels corresponding to T1&#x02013;T3 groups are visualized using Model 1, with modification for zinc. The term &#x0201c;log-transformed zinc&#x0201d; was replaced by &#x0201c;T1&#x02013;T3 &#x000d7; time course&#x0201d; to reflect the interaction between zinc levels (T1&#x02013;T3 groups) and the time course.</p></sec><sec id="sec2dot4dot4-vaccines-12-01359"><title>2.4.4. Sensitivity Analysis</title><p>Among the 45 female participants, one with dyslipidemia was excluded from the sensitivity analysis, resulting in 44 participants with a total of 245 data points. When conducting additional analyses, we considered body weight instead of height.</p></sec></sec></sec><sec sec-type="results" id="sec3-vaccines-12-01359"><title>3. Results</title><sec id="sec3dot1-vaccines-12-01359"><title>3.1. Baseline Characteristics</title><p>During the observation period, all participants had anti-N IgG levels below 1.2 SU/m, indicating no previous exposure to the virus or vaccination. <xref rid="vaccines-12-01359-t001" ref-type="table">Table 1</xref> shows the baseline characteristics of the 79 participants. The study group comprised 45 female (57%) and 34 male participants (43%) with an age range of 21&#x02013;56 years. The baseline characteristics of the participants are presented in <xref rid="vaccines-12-01359-t001" ref-type="table">Table 1</xref>, which categorizes them into three quantiles (T) based on baseline serum zinc levels by sex. The distribution of exercise habits and perceived stress did not differ among the tertiles (female, <italic toggle="yes">p</italic> &#x0003e; 0.6; male, <italic toggle="yes">p</italic> &#x0003e; 0.8, Fisher&#x02019;s exact test). Two male participants in the T3 group reported steroid use, whereas one female participant in the T1 group reported dyslipidemia.</p></sec><sec id="sec3dot2-vaccines-12-01359"><title>3.2. Effect of Baseline Zinc on Anti-S1 IgM Post-Vaccination</title><p>Although no association between zinc and anti-S1 IgM was found in male participants, a positive effect was observed in female participants. The partial regression coefficient (&#x003b2;) for log-transformed zinc on log-transformed anti-S1 IgM (SU/mL) was 2.2 (<italic toggle="yes">p</italic> &#x0003c; 0.001) and 1.5 (<italic toggle="yes">p</italic> = 0.012) in Models 1 and 2, respectively (<xref rid="vaccines-12-01359-t002" ref-type="table">Table 2</xref>). As shown in <xref rid="vaccines-12-01359-f003" ref-type="fig">Figure 3</xref> (left panel), anti-S1 IgM levels exhibited the most significant differences at 1&#x02013;3 weeks after the second dose. Participants in the highest zinc tertile (T3; 93&#x02013;113 &#x003bc;g/dL) displayed the highest anti-S1 IgM levels compared to those in the lower tertiles (T1 and T2; 64&#x02013;92 &#x003bc;g/dL). The area under the curve (AUC) of T3 was 2.4 times greater than that of T1.</p></sec><sec id="sec3dot3-vaccines-12-01359"><title>3.3. Effect of Baseline Zinc on Anti-S1 IgG Post-Vaccination</title><p>Similarly to IgM, the positive fixed effect was estimated in females with a &#x003b2; of 1.7 (<italic toggle="yes">p</italic> &#x0003c; 0.001) in Model 1 (<xref rid="vaccines-12-01359-t003" ref-type="table">Table 3</xref>). The positive effect of zinc in female individuals remained after the inclusion of lifestyle habits and current medical history (&#x003b2; = 1.1, <italic toggle="yes">p</italic> = 0.013 in Model 2). Similarly to the IgG response, anti-S1 IgG levels differed most significantly 1&#x02013;3 weeks after the second dose (<xref rid="vaccines-12-01359-f003" ref-type="fig">Figure 3</xref>). The highest zinc tertile displayed the highest anti-S1 IgG levels compared to those in the lower tertiles, suggesting a beneficial effect of higher pre-vaccination zinc levels on the post-vaccination humoral immune response. The AUC of T3 was 1.6 times greater than that of T1.</p></sec><sec id="sec3dot4-vaccines-12-01359"><title>3.4. Sensitivity Analysis</title><p>Sensitivity analysis, excluding one female participant with dyslipidemia (44 female individuals; 245 observations), resulted in a similar estimation (AIC = 659, &#x003b2; = 1.5, <italic toggle="yes">p</italic> = 0.013 in Model 2 for IgM, and AIC = 512, &#x003b2; = 1.1, <italic toggle="yes">p</italic> = 0.013 in Model 2 for IgG). A slightly modified Model 2, including weight instead of height, produced similar estimates (AIC = 681, &#x003b2; = 1.4, and <italic toggle="yes">p</italic> = 0.018 in Model 2 for IgM, and AIC = 536, &#x003b2; = 1.1, and <italic toggle="yes">p</italic> = 0.013 in Model 2 for IgG).</p></sec></sec><sec sec-type="discussion" id="sec4-vaccines-12-01359"><title>4. Discussion</title><p>Our prospective study investigated the impact of baseline blood zinc levels on the humoral immune response and production of anti-S1 IgG and IgM antibodies following COVID-19 mRNA vaccination in a Japanese cohort. Using mixed models considering repeated measures and covariates, we found higher post-vaccine IgG/IgM production in female participants with higher baseline zinc levels within the normal range, suggesting a positive effect of adequate zinc levels on optimal immune system activity. Such an association was not found in male participants, probably because only one participant was included in the subcohort with frequent repeated measurements (10 repeats in 4 months)<underline>.</underline></p><p>Zinc may increase antibody titers via various pathways [<xref rid="B30-vaccines-12-01359" ref-type="bibr">30</xref>]. For example, zinc may increase the downstream signal interleukin-2 by maintaining the three-dimensional structure of NF&#x003ba;B, thereby increasing the production of IgG [<xref rid="B31-vaccines-12-01359" ref-type="bibr">31</xref>] and IgM [<xref rid="B32-vaccines-12-01359" ref-type="bibr">32</xref>]. Additionally, zinc is crucial for regulating T follicular helper (Tfh) cell production and plays a vital role in humoral immunity [<xref rid="B9-vaccines-12-01359" ref-type="bibr">9</xref>]. The zinc-dependent transcription factor, B-cell lymphoma 6 (BCL6), is particularly important, as it requires zinc for structural integrity to support B-cell maturation within germinal centers. BCL6 regulates B cell and Tfh cell interactions, facilitates antibody class switching, and promotes humoral immunity by upregulating key downstream proteins [<xref rid="B33-vaccines-12-01359" ref-type="bibr">33</xref>].</p><p>Our finding of a significant correlation between baseline zinc levels and antibody response to mRNA vaccination is inconsistent with that of a previous study conducted on a German population [<xref rid="B19-vaccines-12-01359" ref-type="bibr">19</xref>]. One of the advantages of our design over that of this study is the inclusion of multiple covariates; however, multivariate adjustment did not affect this association. The strong impact observed 1&#x02013;3 weeks after the second dose in our study suggests that the frequent observation points played a crucial role in detecting significant associations. In contrast, the previous study lacked observations within the first month post-vaccination [<xref rid="B19-vaccines-12-01359" ref-type="bibr">19</xref>], whereas we conducted four observations within this period.</p><sec><title>Limitations</title><p>This study had a small sample size with a convenience sample, particularly among male participants, which limits the generalizability of the results. Additionally, the small sample size limits the power to detect significance detection for each observation time point over a wide range, which limits the interpretation of the results. For example, based on our observation, a sample size of 400 or more would be required to detect a significant association in the female T1&#x02013;3 groups at 2 months after the second dose (with a power of 0.8 and an alpha error of 0.05). Given the small sample size, these findings need to be validated in larger cohorts. However, with the widespread spread of COVID-19, conducting similar prospective studies in human populations may no longer be feasible. Future efforts should focus on leveraging remaining samples from existing cohorts and conducting confirmatory animal studies to further investigate the relationship between baseline zinc levels and the immune response to COVID-19 vaccination. Additionally, as blood zinc levels would be transiently elevated when humoral immunity is activated [<xref rid="B19-vaccines-12-01359" ref-type="bibr">19</xref>], there is a possibility of misclassifying baseline zinc levels due to the infectious status of the participants. However, as the participants in this study were in a healthy state suitable for receiving the COVID-19 vaccine, we consider this possibility to be less likely. Finally, the uncertainty of the clinical impact should be addressed. According to our observations, the AUC for IgM and IgG in the T3 group were 2.4-fold and 1.6-fold higher than those in the T1 group, suggesting that the effect on IgM may be greater, but further confirmation is needed.</p></sec></sec><sec sec-type="conclusions" id="sec5-vaccines-12-01359"><title>5. Conclusions</title><p>Our prospective study reported a positive association between baseline blood zinc levels and humoral immune response to COVID-19 vaccination in a Japanese population. This finding suggests the importance of assessing blood zinc prior to vaccination, as managing zinc concentrations through appropriate dietary and lifestyle modifications may enhance vaccine efficacy.</p></sec></body><back><ack><title>Acknowledgments</title><p>We thank Miyuki Fuchigami, Mikako Horita, Nobuko Sato, Ayako Ajishi, and Miwako Koga for their administrative and technical support. We also thank Mizuho A. Kido, Histology and Neuroanatomy, Department of Anatomy and Physiology, Faculty of Medicine, Saga University, for educational assistance. Finally, we acknowledge the students, healthcare workers, and employees of Saga University for participating in the present study and for donating blood samples to evaluate humoral immune responses after vaccination.</p></ack><fn-group><fn><p><bold>Disclaimer/Publisher&#x02019;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><notes><title>Author Contributions</title><p>Conceptualization, M.H. and A.M.; methodology, M.H. and A.M.; formal analysis, M.S.A.; investigation, M.H., A.M., M.T. and G.Y.; resources, M.H. and A.M.; data curation, M.H. and A.M.; writing&#x02014;original draft preparation, M.S.A. and A.M.; writing&#x02014;review and editing, all authors; visualization, M.S.A.; supervision, M.H. and A.M.; project administration, M.H.; funding acquisition, M.H. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Ethics Committee for Clinical Research of the School of Medicine at Saga University (approval number: R2&#x02013;44; date of approval: 25 March 2021, R3&#x02013;9; date of approval: 28 April 2021, R3&#x02013;39; date of approval: 24 November 2021) and the Human Genome/Gene Research Ethics Committee of Saga University (approval number: R2&#x02013;24; date of approval: 25 March 2021, R3&#x02013;4; date of approval: 28 April 2021).</p></notes><notes><title>Informed Consent Statement</title><p>Informed consent was obtained from all participants involved in the study. Written informed consent was obtained from the patients prior to the publication of this paper.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>Data presented in this study are available upon request from the corresponding author (A.M.). The data are not publicly available due to privacy concerns.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest. The funder had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.</p></notes><ref-list><title>References</title><ref id="B1-vaccines-12-01359"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cai</surname><given-names>Y.</given-names></name>
<name><surname>Kim</surname><given-names>D.J.</given-names></name>
<name><surname>Takahashi</surname><given-names>T.</given-names></name>
<name><surname>Broadhurst</surname><given-names>D.I.</given-names></name>
<name><surname>Ma</surname><given-names>S.</given-names></name>
<name><surname>Rattray</surname><given-names>N.J.W.</given-names></name>
<name><surname>Casanovas-Massana</surname><given-names>A.</given-names></name>
<name><surname>Israelow</surname><given-names>B.</given-names></name>
<name><surname>Klein</surname><given-names>J.</given-names></name>
<name><surname>Lucas</surname><given-names>C.</given-names></name>
<etal/>
</person-group><article-title>Kynurenic acid underlies sex-specific immune responses to COVID-19</article-title><source>medRxiv</source><year>2021</year><volume>14</volume><fpage>eabf8483</fpage></element-citation></ref><ref id="B2-vaccines-12-01359"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bechmann</surname><given-names>N.</given-names></name>
<name><surname>Barthel</surname><given-names>A.</given-names></name>
<name><surname>Schedl</surname><given-names>A.</given-names></name>
<name><surname>Herzig</surname><given-names>S.</given-names></name>
<name><surname>Varga</surname><given-names>Z.</given-names></name>
<name><surname>Gebhard</surname><given-names>C.</given-names></name>
<name><surname>Mayr</surname><given-names>M.</given-names></name>
<name><surname>Hantel</surname><given-names>C.</given-names></name>
<name><surname>Beuschlein</surname><given-names>F.</given-names></name>
<name><surname>Wolfrum</surname><given-names>C.</given-names></name>
<etal/>
</person-group><article-title>Sexual dimorphism in COVID-19: Potential clinical and public health implications</article-title><source>Lancet Diabetes Endocrinol.</source><year>2022</year><volume>10</volume><fpage>221</fpage><lpage>230</lpage><pub-id pub-id-type="doi">10.1016/S2213-8587(21)00346-6</pub-id><pub-id pub-id-type="pmid">35114136</pub-id>
</element-citation></ref><ref id="B3-vaccines-12-01359"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Arnold</surname><given-names>C.G.</given-names></name>
<name><surname>Libby</surname><given-names>A.</given-names></name>
<name><surname>Vest</surname><given-names>A.</given-names></name>
<name><surname>Hopkinson</surname><given-names>A.</given-names></name>
<name><surname>Monte</surname><given-names>A.A.</given-names></name>
</person-group><article-title>Immune mechanisms associated with sex-based differences in severe COVID-19 clinical outcomes</article-title><source>Biol. Sex Differ.</source><year>2022</year><volume>13</volume><elocation-id>7</elocation-id><pub-id pub-id-type="doi">10.1186/s13293-022-00417-3</pub-id><pub-id pub-id-type="pmid">35246245</pub-id>
</element-citation></ref><ref id="B4-vaccines-12-01359"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Galmes</surname><given-names>S.</given-names></name>
<name><surname>Serra</surname><given-names>F.</given-names></name>
<name><surname>Palou</surname><given-names>A.</given-names></name>
</person-group><article-title>Current State of Evidence: Influence of Nutritional and Nutrigenetic Factors on Immunity in the COVID-19 Pandemic Framework</article-title><source>Nutrients</source><year>2020</year><volume>12</volume><elocation-id>2738</elocation-id><pub-id pub-id-type="doi">10.3390/nu12092738</pub-id><pub-id pub-id-type="pmid">32911778</pub-id>
</element-citation></ref><ref id="B5-vaccines-12-01359"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>de Faria Coelho-Ravagnani</surname><given-names>C.</given-names></name>
<name><surname>Corgosinho</surname><given-names>F.C.</given-names></name>
<name><surname>Sanches</surname><given-names>F.F.Z.</given-names></name>
<name><surname>Prado</surname><given-names>C.M.M.</given-names></name>
<name><surname>Laviano</surname><given-names>A.</given-names></name>
<name><surname>Mota</surname><given-names>J.F.</given-names></name>
</person-group><article-title>Dietary recommendations during the COVID-19 pandemic</article-title><source>Nutr. Rev.</source><year>2021</year><volume>79</volume><fpage>382</fpage><lpage>393</lpage><pub-id pub-id-type="doi">10.1093/nutrit/nuaa067</pub-id><pub-id pub-id-type="pmid">32653930</pub-id>
</element-citation></ref><ref id="B6-vaccines-12-01359"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Richardson</surname><given-names>D.P.</given-names></name>
<name><surname>Lovegrove</surname><given-names>J.A.</given-names></name>
</person-group><article-title>Nutritional status of micronutrients as a possible and modifiable risk factor for COVID-19: A UK perspective</article-title><source>Br. J. Nutr.</source><year>2021</year><volume>125</volume><fpage>678</fpage><lpage>684</lpage><pub-id pub-id-type="doi">10.1017/S000711452000330X</pub-id><pub-id pub-id-type="pmid">32815493</pub-id>
</element-citation></ref><ref id="B7-vaccines-12-01359"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Schubert</surname><given-names>C.</given-names></name>
<name><surname>Guttek</surname><given-names>K.</given-names></name>
<name><surname>Reinhold</surname><given-names>A.</given-names></name>
<name><surname>Gr&#x000fc;ngreiff</surname><given-names>K.</given-names></name>
<name><surname>Reinhold</surname><given-names>D.</given-names></name>
</person-group><article-title>The influence of the trace element zinc on the immune system</article-title><source>Lab. Med.</source><year>2015</year><volume>39</volume><fpage>000010151520150060</fpage><pub-id pub-id-type="doi">10.1515/labmed-2015-0060</pub-id></element-citation></ref><ref id="B8-vaccines-12-01359"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Maares</surname><given-names>M.</given-names></name>
<name><surname>Haase</surname><given-names>H.</given-names></name>
</person-group><article-title>Zinc and immunity: An essential interrelation</article-title><source>Arch. Biochem. Biophys.</source><year>2016</year><volume>611</volume><fpage>58</fpage><lpage>65</lpage><pub-id pub-id-type="doi">10.1016/j.abb.2016.03.022</pub-id><pub-id pub-id-type="pmid">27021581</pub-id>
</element-citation></ref><ref id="B9-vaccines-12-01359"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hojyo</surname><given-names>S.</given-names></name>
<name><surname>Fukada</surname><given-names>T.</given-names></name>
</person-group><article-title>Roles of Zinc Signaling in the Immune System</article-title><source>J. Immunol. Res.</source><year>2016</year><volume>2016</volume><fpage>6762343</fpage><pub-id pub-id-type="doi">10.1155/2016/6762343</pub-id><pub-id pub-id-type="pmid">27872866</pub-id>
</element-citation></ref><ref id="B10-vaccines-12-01359"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gorji</surname><given-names>A.</given-names></name>
<name><surname>Khaleghi Ghadiri</surname><given-names>M.</given-names></name>
</person-group><article-title>Potential roles of micronutrient deficiency and immune system dysfunction in the coronavirus disease 2019 (COVID-19) pandemic</article-title><source>Nutrition</source><year>2021</year><volume>82</volume><fpage>111047</fpage><pub-id pub-id-type="doi">10.1016/j.nut.2020.111047</pub-id><pub-id pub-id-type="pmid">33277150</pub-id>
</element-citation></ref><ref id="B11-vaccines-12-01359"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Marshall</surname><given-names>J.S.</given-names></name>
<name><surname>Warrington</surname><given-names>R.</given-names></name>
<name><surname>Watson</surname><given-names>W.</given-names></name>
<name><surname>Kim</surname><given-names>H.L.</given-names></name>
</person-group><article-title>An introduction to immunology and immunopathology</article-title><source>Allergy Asthma Clin. Immunol.</source><year>2018</year><volume>14</volume><fpage>49</fpage><pub-id pub-id-type="doi">10.1186/s13223-018-0278-1</pub-id><pub-id pub-id-type="pmid">30263032</pub-id>
</element-citation></ref><ref id="B12-vaccines-12-01359"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Meydani</surname><given-names>S.N.</given-names></name>
<name><surname>Barnett</surname><given-names>J.B.</given-names></name>
<name><surname>Dallal</surname><given-names>G.E.</given-names></name>
<name><surname>Fine</surname><given-names>B.C.</given-names></name>
<name><surname>Jacques</surname><given-names>P.F.</given-names></name>
<name><surname>Leka</surname><given-names>L.S.</given-names></name>
<name><surname>Hamer</surname><given-names>D.H.</given-names></name>
</person-group><article-title>Serum zinc and pneumonia in nursing home elderly</article-title><source>Am. J. Clin. Nutr.</source><year>2007</year><volume>86</volume><fpage>1167</fpage><lpage>1173</lpage><pub-id pub-id-type="doi">10.1093/ajcn/86.4.1167</pub-id><pub-id pub-id-type="pmid">17921398</pub-id>
</element-citation></ref><ref id="B13-vaccines-12-01359"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Heller</surname><given-names>R.A.</given-names></name>
<name><surname>Sun</surname><given-names>Q.</given-names></name>
<name><surname>Hackler</surname><given-names>J.</given-names></name>
<name><surname>Seelig</surname><given-names>J.</given-names></name>
<name><surname>Seibert</surname><given-names>L.</given-names></name>
<name><surname>Cherkezov</surname><given-names>A.</given-names></name>
<name><surname>Minich</surname><given-names>W.B.</given-names></name>
<name><surname>Seemann</surname><given-names>P.</given-names></name>
<name><surname>Diegmann</surname><given-names>J.</given-names></name>
<name><surname>Pilz</surname><given-names>M.</given-names></name>
<etal/>
</person-group><article-title>Prediction of survival odds in COVID-19 by zinc, age and selenoprotein P as composite biomarker</article-title><source>Redox Biol.</source><year>2021</year><volume>38</volume><elocation-id>101764</elocation-id><pub-id pub-id-type="doi">10.1016/j.redox.2020.101764</pub-id><pub-id pub-id-type="pmid">33126054</pub-id>
</element-citation></ref><ref id="B14-vaccines-12-01359"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jothimani</surname><given-names>D.</given-names></name>
<name><surname>Kailasam</surname><given-names>E.</given-names></name>
<name><surname>Danielraj</surname><given-names>S.</given-names></name>
<name><surname>Nallathambi</surname><given-names>B.</given-names></name>
<name><surname>Ramachandran</surname><given-names>H.</given-names></name>
<name><surname>Sekar</surname><given-names>P.</given-names></name>
<name><surname>Manoharan</surname><given-names>S.</given-names></name>
<name><surname>Ramani</surname><given-names>V.</given-names></name>
<name><surname>Narasimhan</surname><given-names>G.</given-names></name>
<name><surname>Kaliamoorthy</surname><given-names>I.</given-names></name>
<etal/>
</person-group><article-title>COVID-19: Poor outcomes in patients with zinc deficiency</article-title><source>Int. J. Infect. Dis.</source><year>2020</year><volume>100</volume><fpage>343</fpage><lpage>349</lpage><pub-id pub-id-type="doi">10.1016/j.ijid.2020.09.014</pub-id><pub-id pub-id-type="pmid">32920234</pub-id>
</element-citation></ref><ref id="B15-vaccines-12-01359"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bagher Pour</surname><given-names>O.</given-names></name>
<name><surname>Yahyavi</surname><given-names>Y.</given-names></name>
<name><surname>Karimi</surname><given-names>A.</given-names></name>
<name><surname>Khamaneh</surname><given-names>A.M.</given-names></name>
<name><surname>Milani</surname><given-names>M.</given-names></name>
<name><surname>Khalili</surname><given-names>M.</given-names></name>
<name><surname>Sharifi</surname><given-names>A.</given-names></name>
</person-group><article-title>Serum trace elements levels and clinical outcomes among Iranian COVID-19 patients</article-title><source>Int. J. Infect. Dis.</source><year>2021</year><volume>111</volume><fpage>164</fpage><lpage>168</lpage><pub-id pub-id-type="doi">10.1016/j.ijid.2021.08.053</pub-id><pub-id pub-id-type="pmid">34454118</pub-id>
</element-citation></ref><ref id="B16-vaccines-12-01359"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mossink</surname><given-names>J.P.</given-names></name>
</person-group><article-title>Zinc as nutritional intervention and prevention measure for COVID-19 disease</article-title><source>BMJ Nutr. Prev. Health</source><year>2020</year><volume>3</volume><fpage>111</fpage><lpage>117</lpage><pub-id pub-id-type="doi">10.1136/bmjnph-2020-000095</pub-id></element-citation></ref><ref id="B17-vaccines-12-01359"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rahman</surname><given-names>M.T.</given-names></name>
<name><surname>Idid</surname><given-names>S.Z.</given-names></name>
</person-group><article-title>Can Zn Be a Critical Element in COVID-19 Treatment?</article-title><source>Biol. Trace Elem. Res.</source><year>2021</year><volume>199</volume><fpage>550</fpage><lpage>558</lpage><pub-id pub-id-type="doi">10.1007/s12011-020-02194-9</pub-id><pub-id pub-id-type="pmid">32458149</pub-id>
</element-citation></ref><ref id="B18-vaccines-12-01359"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Razzaque</surname><given-names>M.S.</given-names></name>
</person-group><article-title>COVID-19 pandemic: Can zinc supplementation provide an additional shield against the infection?</article-title><source>Comput. Struct. Biotechnol. J.</source><year>2021</year><volume>19</volume><fpage>1371</fpage><lpage>1378</lpage><pub-id pub-id-type="doi">10.1016/j.csbj.2021.02.015</pub-id><pub-id pub-id-type="pmid">33680350</pub-id>
</element-citation></ref><ref id="B19-vaccines-12-01359"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chillon</surname><given-names>T.S.</given-names></name>
<name><surname>Maares</surname><given-names>M.</given-names></name>
<name><surname>Demircan</surname><given-names>K.</given-names></name>
<name><surname>Hackler</surname><given-names>J.</given-names></name>
<name><surname>Sun</surname><given-names>Q.</given-names></name>
<name><surname>Heller</surname><given-names>R.A.</given-names></name>
<name><surname>Diegmann</surname><given-names>J.</given-names></name>
<name><surname>Bachmann</surname><given-names>M.</given-names></name>
<name><surname>Moghaddam</surname><given-names>A.</given-names></name>
<name><surname>Haase</surname><given-names>H.</given-names></name>
<etal/>
</person-group><article-title>Serum Free Zinc Is Associated With Vaccination Response to SARS-CoV-2</article-title><source>Front. Immunol.</source><year>2022</year><volume>13</volume><elocation-id>2738</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2022.906551</pub-id></element-citation></ref><ref id="B20-vaccines-12-01359"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lopresti</surname><given-names>A.L.</given-names></name>
</person-group><article-title>The Effects of Psychological and Environmental Stress on Micronutrient Concentrations in the Body: A Review of the Evidence</article-title><source>Adv. Nutr.</source><year>2020</year><volume>11</volume><fpage>103</fpage><lpage>112</lpage><pub-id pub-id-type="doi">10.1093/advances/nmz082</pub-id><pub-id pub-id-type="pmid">31504084</pub-id>
</element-citation></ref><ref id="B21-vaccines-12-01359"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ashenagar</surname><given-names>M.S.</given-names></name>
<name><surname>Matsumoto</surname><given-names>A.</given-names></name>
<name><surname>Sakai</surname><given-names>H.</given-names></name>
<name><surname>Tokiya</surname><given-names>M.</given-names></name>
<name><surname>Hara</surname><given-names>M.</given-names></name>
<name><surname>Hirota</surname><given-names>Y.</given-names></name>
</person-group><article-title>Comparison of CLEIA and ELISA for SARS-CoV-2 Virus Antibodies after First and Second Dose Vaccinations with the BNT162b2 mRNA Vaccine</article-title><source>Vaccines</source><year>2022</year><volume>10</volume><elocation-id>487</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines10040487</pub-id><pub-id pub-id-type="pmid">35455236</pub-id>
</element-citation></ref><ref id="B22-vaccines-12-01359"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Matsumoto</surname><given-names>A.</given-names></name>
<name><surname>Hara</surname><given-names>M.</given-names></name>
<name><surname>Ashenagar</surname><given-names>M.S.</given-names></name>
<name><surname>Tokiya</surname><given-names>M.</given-names></name>
<name><surname>Sawada</surname><given-names>T.</given-names></name>
<name><surname>Iwasaka</surname><given-names>C.</given-names></name>
<name><surname>Furukawa</surname><given-names>T.</given-names></name>
<name><surname>Kitagawa</surname><given-names>K.</given-names></name>
<name><surname>Miyake</surname><given-names>Y.</given-names></name>
<name><surname>Hirota</surname><given-names>Y.</given-names></name>
</person-group><article-title>Variant Allele of ALDH2, rs671, Associates with Attenuated Post-Vaccination Response in Anti-SARS-CoV-2 Spike Protein IgG: A Prospective Study in the Japanese General Population</article-title><source>Vaccines</source><year>2022</year><volume>10</volume><elocation-id>1035</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines10071035</pub-id><pub-id pub-id-type="pmid">35891198</pub-id>
</element-citation></ref><ref id="B23-vaccines-12-01359"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kageyama</surname><given-names>T.</given-names></name>
<name><surname>Ikeda</surname><given-names>K.</given-names></name>
<name><surname>Tanaka</surname><given-names>S.</given-names></name>
<name><surname>Taniguchi</surname><given-names>T.</given-names></name>
<name><surname>Igari</surname><given-names>H.</given-names></name>
<name><surname>Onouchi</surname><given-names>Y.</given-names></name>
<name><surname>Kaneda</surname><given-names>A.</given-names></name>
<name><surname>Matsushita</surname><given-names>K.</given-names></name>
<name><surname>Hanaoka</surname><given-names>H.</given-names></name>
<name><surname>Nakada</surname><given-names>T.A.</given-names></name>
<etal/>
</person-group><article-title>Antibody responses to BNT162b2 mRNA COVID-19 vaccine and their predictors among healthcare workers in a tertiary referral hospital in Japan</article-title><source>Clin. Microbiol. Infect.</source><year>2021</year><volume>27</volume><elocation-id>e1861</elocation-id><pub-id pub-id-type="doi">10.1016/j.cmi.2021.07.042</pub-id><pub-id pub-id-type="pmid">34375755</pub-id>
</element-citation></ref><ref id="B24-vaccines-12-01359"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zheng</surname><given-names>C.</given-names></name>
<name><surname>Shao</surname><given-names>W.</given-names></name>
<name><surname>Chen</surname><given-names>X.</given-names></name>
<name><surname>Zhang</surname><given-names>B.</given-names></name>
<name><surname>Wang</surname><given-names>G.</given-names></name>
<name><surname>Zhang</surname><given-names>W.</given-names></name>
</person-group><article-title>Real-world effectiveness of COVID-19 vaccines: A literature review and meta-analysis</article-title><source>Int. J. Infect. Dis.</source><year>2022</year><volume>114</volume><fpage>252</fpage><lpage>260</lpage><pub-id pub-id-type="doi">10.1016/j.ijid.2021.11.009</pub-id><pub-id pub-id-type="pmid">34800687</pub-id>
</element-citation></ref><ref id="B25-vaccines-12-01359"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Deb</surname><given-names>P.</given-names></name>
<name><surname>Zannat</surname><given-names>K.E.</given-names></name>
<name><surname>Talukder</surname><given-names>S.</given-names></name>
<name><surname>Bhuiyan</surname><given-names>A.H.</given-names></name>
<name><surname>Jilani</surname><given-names>M.S.A.</given-names></name>
<name><surname>Saif-Ur-Rahman</surname><given-names>K.M.</given-names></name>
</person-group><article-title>Association of HLA gene polymorphism with susceptibility, severity, and mortality of COVID-19: A systematic review</article-title><source>HLA</source><year>2022</year><volume>99</volume><fpage>281</fpage><lpage>312</lpage><pub-id pub-id-type="doi">10.1111/tan.14560</pub-id><pub-id pub-id-type="pmid">35067002</pub-id>
</element-citation></ref><ref id="B26-vaccines-12-01359"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shimanoe</surname><given-names>C.</given-names></name>
<name><surname>Matsumoto</surname><given-names>A.</given-names></name>
<name><surname>Hara</surname><given-names>M.</given-names></name>
<name><surname>Akao</surname><given-names>C.</given-names></name>
<name><surname>Nishida</surname><given-names>Y.</given-names></name>
<name><surname>Horita</surname><given-names>M.</given-names></name>
<name><surname>Nanri</surname><given-names>H.</given-names></name>
<name><surname>Higaki</surname><given-names>Y.</given-names></name>
<name><surname>Tanaka</surname><given-names>K.</given-names></name>
</person-group><article-title>Perceived stress, depressive symptoms, and cortisol-to-cortisone ratio in spot urine in 6878 older adults</article-title><source>Psychoneuroendocrinology</source><year>2021</year><volume>125</volume><fpage>105125</fpage><pub-id pub-id-type="doi">10.1016/j.psyneuen.2020.105125</pub-id><pub-id pub-id-type="pmid">33429220</pub-id>
</element-citation></ref><ref id="B27-vaccines-12-01359"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Salimans</surname><given-names>L.</given-names></name>
<name><surname>Liberman</surname><given-names>K.</given-names></name>
<name><surname>Njemini</surname><given-names>R.</given-names></name>
<name><surname>Kortekaas Krohn</surname><given-names>I.</given-names></name>
<name><surname>Gutermuth</surname><given-names>J.</given-names></name>
<name><surname>Bautmans</surname><given-names>I.</given-names></name>
</person-group><article-title>The effect of resistance exercise on the immune cell function in humans: A systematic review</article-title><source>Exp. Gerontol.</source><year>2022</year><volume>164</volume><fpage>111822</fpage><pub-id pub-id-type="doi">10.1016/j.exger.2022.111822</pub-id><pub-id pub-id-type="pmid">35490790</pub-id>
</element-citation></ref><ref id="B28-vaccines-12-01359"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>De Spiegeleer</surname><given-names>A.</given-names></name>
<name><surname>Bronselaer</surname><given-names>A.</given-names></name>
<name><surname>Teo</surname><given-names>J.T.</given-names></name>
<name><surname>Byttebier</surname><given-names>G.</given-names></name>
<name><surname>De Tre</surname><given-names>G.</given-names></name>
<name><surname>Belmans</surname><given-names>L.</given-names></name>
<name><surname>Dobson</surname><given-names>R.</given-names></name>
<name><surname>Wynendaele</surname><given-names>E.</given-names></name>
<name><surname>Van De Wiele</surname><given-names>C.</given-names></name>
<name><surname>Vandaele</surname><given-names>F.</given-names></name>
<etal/>
</person-group><article-title>The Effects of ARBs, ACEis, and Statins on Clinical Outcomes of COVID-19 Infection Among Nursing Home Residents</article-title><source>J. Am. Med. Dir. Assoc.</source><year>2020</year><volume>21</volume><fpage>909</fpage><lpage>914</lpage><page-range>909&#x02013;914.e2</page-range><pub-id pub-id-type="doi">10.1016/j.jamda.2020.06.018</pub-id><pub-id pub-id-type="pmid">32674818</pub-id>
</element-citation></ref><ref id="B29-vaccines-12-01359"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Daniels</surname><given-names>L.B.</given-names></name>
<name><surname>Sitapati</surname><given-names>A.M.</given-names></name>
<name><surname>Zhang</surname><given-names>J.</given-names></name>
<name><surname>Zou</surname><given-names>J.</given-names></name>
<name><surname>Bui</surname><given-names>Q.M.</given-names></name>
<name><surname>Ren</surname><given-names>J.</given-names></name>
<name><surname>Longhurst</surname><given-names>C.A.</given-names></name>
<name><surname>Criqui</surname><given-names>M.H.</given-names></name>
<name><surname>Messer</surname><given-names>K.</given-names></name>
</person-group><article-title>Relation of Statin Use Prior to Admission to Severity and Recovery Among COVID-19 Inpatients</article-title><source>Am. J. Cardiol.</source><year>2020</year><volume>136</volume><fpage>149</fpage><lpage>155</lpage><pub-id pub-id-type="doi">10.1016/j.amjcard.2020.09.012</pub-id><pub-id pub-id-type="pmid">32946859</pub-id>
</element-citation></ref><ref id="B30-vaccines-12-01359"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Haase</surname><given-names>H.</given-names></name>
<name><surname>Rink</surname><given-names>L.</given-names></name>
</person-group><article-title>Zinc signals and immune function</article-title><source>Biofactors</source><year>2014</year><volume>40</volume><fpage>27</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1002/biof.1114</pub-id><pub-id pub-id-type="pmid">23804522</pub-id>
</element-citation></ref><ref id="B31-vaccines-12-01359"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kawano</surname><given-names>Y.</given-names></name>
<name><surname>Noma</surname><given-names>T.</given-names></name>
</person-group><article-title>Role of interleukin-2 and interferon-gamma in inducing production of IgG subclasses in lymphocytes of human newborns</article-title><source>Immunology</source><year>1996</year><volume>88</volume><fpage>40</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2567.1996.d01-634.x</pub-id><pub-id pub-id-type="pmid">8707348</pub-id>
</element-citation></ref><ref id="B32-vaccines-12-01359"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sauerwein</surname><given-names>R.W.</given-names></name>
<name><surname>Van der Meer</surname><given-names>W.G.</given-names></name>
<name><surname>Drager</surname><given-names>A.</given-names></name>
<name><surname>Aarden</surname><given-names>L.A.</given-names></name>
</person-group><article-title>Interleukin 2 induces T cell-dependent IgM production in human B cells</article-title><source>Eur. J. Immunol.</source><year>1985</year><volume>15</volume><fpage>611</fpage><lpage>616</lpage><pub-id pub-id-type="doi">10.1002/eji.1830150615</pub-id><pub-id pub-id-type="pmid">3874074</pub-id>
</element-citation></ref><ref id="B33-vaccines-12-01359"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mascle</surname><given-names>X.</given-names></name>
<name><surname>Albagli</surname><given-names>O.</given-names></name>
<name><surname>Lemercier</surname><given-names>C.</given-names></name>
</person-group><article-title>Point mutations in BCL6 DNA-binding domain reveal distinct roles for the six zinc fingers</article-title><source>Biochem. Biophys. Res. Commun.</source><year>2003</year><volume>300</volume><fpage>391</fpage><lpage>396</lpage><pub-id pub-id-type="doi">10.1016/S0006-291X(02)02873-5</pub-id><pub-id pub-id-type="pmid">12504096</pub-id>
</element-citation></ref></ref-list></back><floats-group><fig position="float" id="vaccines-12-01359-f001"><label>Figure 1</label><caption><p>Study design. All participants, including healthcare workers, university students, and employees, received two doses of the Pfizer and Moderna (BioNTech) COVID-19 vaccines. Blood samples were collected at Week 0 and at various intervals up to Week 12 after the second vaccination from healthcare workers (Subcohort 1), university students (Subcohort 2), and university employees and students (Subcohort 3).</p></caption><graphic xlink:href="vaccines-12-01359-g001" position="float"/></fig><fig position="float" id="vaccines-12-01359-f002"><label>Figure 2</label><caption><p>Zinc levels according to sex and distribution. The total blood zinc levels are displayed as dots for each individual, categorized by sex (male and female). The bars represent the median zinc levels, and the error bars indicate the interquartile range. The <italic toggle="yes">p</italic>-value was used for Spearman&#x02019;s rank correlation between sex and zinc levels (<bold>a</bold>). The histograms (<bold>b</bold>) represent the distribution of zinc levels separately for male and female individuals. The gray-shaded area corresponds to zinc deficiency (&#x0003c;80 &#x003bc;g/dL) according to the general standards in Japanese hospitals, allowing for the comparison of the zinc deficiency prevalence between sexes.</p></caption><graphic xlink:href="vaccines-12-01359-g002" position="float"/></fig><fig position="float" id="vaccines-12-01359-f003"><label>Figure 3</label><caption><p>Estimated anti-S1 IgM and IgG levels after the second dose in female participants. Least-squares geometric means and standard errors were calculated using mixed models that account for vaccine type, age, and the interaction between zinc levels (T1, T2, and T3 as class variables) and the number of weeks post-vaccination (as a class variable). The models include random effects based on repeated measures and the three cohorts. Binding antibody units (BAU) were calibrated against the WHO international standard, and the x-axis is displayed on a log-2 scale for improved visualization. SU, Sysmex unit.</p></caption><graphic xlink:href="vaccines-12-01359-g003" position="float"/></fig><table-wrap position="float" id="vaccines-12-01359-t001"><object-id pub-id-type="pii">vaccines-12-01359-t001_Table 1</object-id><label>Table 1</label><caption><p>Baseline characteristics of the participants.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th><th colspan="3" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Male</th><th colspan="3" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Female</th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">Serum zinc categories</td><td align="center" valign="middle" rowspan="1" colspan="1">T1</td><td align="center" valign="middle" rowspan="1" colspan="1">T2</td><td align="center" valign="middle" rowspan="1" colspan="1">T3</td><td align="center" valign="middle" rowspan="1" colspan="1">T1</td><td align="center" valign="middle" rowspan="1" colspan="1">T2</td><td align="center" valign="middle" rowspan="1" colspan="1">T3</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;Median (&#x003bc;g/dL)</td><td align="center" valign="middle" rowspan="1" colspan="1">90.5</td><td align="center" valign="middle" rowspan="1" colspan="1">103</td><td align="center" valign="middle" rowspan="1" colspan="1">119</td><td align="center" valign="middle" rowspan="1" colspan="1">78.5</td><td align="center" valign="middle" rowspan="1" colspan="1">88.5</td><td align="center" valign="middle" rowspan="1" colspan="1">97</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;Interquartile range (&#x003bc;g/dL)</td><td align="center" valign="middle" rowspan="1" colspan="1">74&#x02013;98</td><td align="center" valign="middle" rowspan="1" colspan="1">99&#x02013;107</td><td align="center" valign="middle" rowspan="1" colspan="1">108&#x02013;140</td><td align="center" valign="middle" rowspan="1" colspan="1">64&#x02013;82</td><td align="center" valign="middle" rowspan="1" colspan="1">83&#x02013;92</td><td align="center" valign="middle" rowspan="1" colspan="1">93&#x02013;113</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Number</td><td align="center" valign="middle" rowspan="1" colspan="1">12</td><td align="center" valign="middle" rowspan="1" colspan="1">11</td><td align="center" valign="middle" rowspan="1" colspan="1">11</td><td align="center" valign="middle" rowspan="1" colspan="1">16</td><td align="center" valign="middle" rowspan="1" colspan="1">14</td><td align="center" valign="middle" rowspan="1" colspan="1">15</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Age, years</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x02003;Median</td><td align="center" valign="middle" rowspan="1" colspan="1">23</td><td align="center" valign="middle" rowspan="1" colspan="1">22</td><td align="center" valign="middle" rowspan="1" colspan="1">23</td><td align="center" valign="middle" rowspan="1" colspan="1">37.7</td><td align="center" valign="middle" rowspan="1" colspan="1">22.2</td><td align="center" valign="middle" rowspan="1" colspan="1">22</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Interquartile range</td><td align="center" valign="middle" rowspan="1" colspan="1">20.7&#x02013;63.0</td><td align="center" valign="middle" rowspan="1" colspan="1">20.5&#x02013;47.2</td><td align="center" valign="middle" rowspan="1" colspan="1">20.9&#x02013;46.8</td><td align="center" valign="middle" rowspan="1" colspan="1">22.0&#x02013;59.0</td><td align="center" valign="middle" rowspan="1" colspan="1">21.3&#x02013;54.0</td><td align="center" valign="middle" rowspan="1" colspan="1">20.7&#x02013;59.6</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Occupation</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Healthcare worker</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">3</td><td align="center" valign="middle" rowspan="1" colspan="1">5</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Student</td><td align="center" valign="middle" rowspan="1" colspan="1">7</td><td align="center" valign="middle" rowspan="1" colspan="1">7</td><td align="center" valign="middle" rowspan="1" colspan="1">8</td><td align="center" valign="middle" rowspan="1" colspan="1">6</td><td align="center" valign="middle" rowspan="1" colspan="1">6</td><td align="center" valign="middle" rowspan="1" colspan="1">8</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">University worker</td><td align="center" valign="middle" rowspan="1" colspan="1">4</td><td align="center" valign="middle" rowspan="1" colspan="1">4</td><td align="center" valign="middle" rowspan="1" colspan="1">3</td><td align="center" valign="middle" rowspan="1" colspan="1">7</td><td align="center" valign="middle" rowspan="1" colspan="1">3</td><td align="center" valign="middle" rowspan="1" colspan="1">5</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Smoking, yes</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Steroid use, yes</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Dyslipidemia</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Perceived stress *</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">0/1/2/3/4</td><td align="center" valign="middle" rowspan="1" colspan="1">3/1/3/5/0</td><td align="center" valign="middle" rowspan="1" colspan="1">5/1/1/3/1</td><td align="center" valign="middle" rowspan="1" colspan="1">5/1/3/2/0</td><td align="center" valign="middle" rowspan="1" colspan="1">2/2/5/5/2</td><td align="center" valign="middle" rowspan="1" colspan="1">4/1/4/4/1</td><td align="center" valign="middle" rowspan="1" colspan="1">6/1/2/5/1</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">rs671 variant allele **</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">0/1/2</td><td align="center" valign="middle" rowspan="1" colspan="1">8/3/1</td><td align="center" valign="middle" rowspan="1" colspan="1">3/5/3</td><td align="center" valign="middle" rowspan="1" colspan="1">4/5/2</td><td align="center" valign="middle" rowspan="1" colspan="1">10/6/0</td><td align="center" valign="middle" rowspan="1" colspan="1">7/6/1</td><td align="center" valign="middle" rowspan="1" colspan="1">10/4/1</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Ethanol, g/day/weight60kg</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#x0003c;1/&#x02265;1, &#x0003c;20/&#x02265;20</td><td align="center" valign="middle" rowspan="1" colspan="1">3/8/1</td><td align="center" valign="middle" rowspan="1" colspan="1">6/4/1</td><td align="center" valign="middle" rowspan="1" colspan="1">6/5/0</td><td align="center" valign="middle" rowspan="1" colspan="1">12/4/0</td><td align="center" valign="middle" rowspan="1" colspan="1">7/5/2</td><td align="center" valign="middle" rowspan="1" colspan="1">11/4/0</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Exercise habit ***</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">0/1/2/3</td><td align="center" valign="middle" rowspan="1" colspan="1">2/4/4/2</td><td align="center" valign="middle" rowspan="1" colspan="1">2/5/2/2</td><td align="center" valign="middle" rowspan="1" colspan="1">3/0/5/3</td><td align="center" valign="middle" rowspan="1" colspan="1">7/1/5/3</td><td align="center" valign="middle" rowspan="1" colspan="1">6/0/5/3</td><td align="center" valign="middle" rowspan="1" colspan="1">10/1/3/1</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Allergic disease, yes</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">0</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">4</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">1</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sleep disturbance</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td></tr></tbody></table><table-wrap-foot><fn><p>* No (0) to yes (4). ** <italic toggle="yes">ALDH2*1/*1</italic> (0), <italic toggle="yes">ALDH2*1/*2</italic> (1), <italic toggle="yes">ALDH2*2/*2</italic> (2). *** No habit (0), less than once a week (1), 1 to 3 days/week (2), and more than 3 days/week (3).</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="vaccines-12-01359-t002"><object-id pub-id-type="pii">vaccines-12-01359-t002_Table 2</object-id><label>Table 2</label><caption><p>Estimation of fixed effects on log-transformed anti-S1 IgM (SU/mL).</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Males</th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">
</th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Females</th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">
</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td colspan="2" align="center" valign="middle" rowspan="1">Model 1</td><td colspan="2" align="center" valign="middle" rowspan="1">Model 2</td><td colspan="2" align="center" valign="middle" rowspan="1">Model 1</td><td colspan="2" align="center" valign="middle" rowspan="1">Model 2</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td colspan="2" align="center" valign="middle" rowspan="1">AIC = 427.1</td><td colspan="2" align="center" valign="middle" rowspan="1">AIC = 419.6</td><td colspan="2" align="center" valign="middle" rowspan="1">AIC = 682</td><td colspan="2" align="center" valign="middle" rowspan="1">AIC = 680</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td colspan="2" align="center" valign="middle" rowspan="1">162 observations</td><td colspan="2" align="center" valign="middle" rowspan="1">162 observations</td><td colspan="2" align="center" valign="middle" rowspan="1">255 observations</td><td colspan="2" align="center" valign="middle" rowspan="1">255 observations</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td colspan="2" align="center" valign="middle" rowspan="1">34 participants</td><td colspan="2" align="center" valign="middle" rowspan="1">34 participants</td><td colspan="2" align="center" valign="middle" rowspan="1">45 participants</td><td colspan="2" align="center" valign="middle" rowspan="1">45 participants</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Fixed effect</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x003b2;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x003b2;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x00392;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x003b2;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">BNT162b2 (reference)</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">mRNA-1273</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.05036</td><td align="center" valign="middle" rowspan="1" colspan="1">0.7928</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.2172</td><td align="center" valign="middle" rowspan="1" colspan="1">0.3295</td><td align="center" valign="middle" rowspan="1" colspan="1">0.251</td><td align="center" valign="middle" rowspan="1" colspan="1">0.1028</td><td align="center" valign="middle" rowspan="1" colspan="1">0.239</td><td align="center" valign="middle" rowspan="1" colspan="1">0.2248</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Age (per year of age)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.01927</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0327</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.00379</td><td align="center" valign="middle" rowspan="1" colspan="1">0.6982</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.00958</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0573</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.005</td><td align="center" valign="middle" rowspan="1" colspan="1">0.4755</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Body height (per cm)</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.01749</td><td align="center" valign="middle" rowspan="1" colspan="1">0.2796</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.012</td><td align="center" valign="middle" rowspan="1" colspan="1">0.3177</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Steroid use, yes</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;1.1015</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0055</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02014;</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Dyslipidemia, yes</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02014;</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02014;</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;1.3556</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0002</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Allergic disease, yes</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">0.1747</td><td align="center" valign="middle" rowspan="1" colspan="1">0.3552</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">0.005</td><td align="center" valign="middle" rowspan="1" colspan="1">0.9729</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Exercise habit (per category)</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">0.01473</td><td align="center" valign="middle" rowspan="1" colspan="1">0.8767</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">0.028</td><td align="center" valign="middle" rowspan="1" colspan="1">0.6047</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Cigarette smoke, yes</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.07372</td><td align="center" valign="middle" rowspan="1" colspan="1">0.9281</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02014;</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Ethanol intake (per category)</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.5076</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0008</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">0.2721</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0139</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Perceived stress (per category)</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.02271</td><td align="center" valign="middle" rowspan="1" colspan="1">0.7359</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0276</td><td align="center" valign="middle" rowspan="1" colspan="1">0.6176</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Sleep disturbance, yes</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.3611</td><td align="center" valign="middle" rowspan="1" colspan="1">0.5297</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.7167</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0124</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Log zinc (&#x003bc;g/dL)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;0.7695</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.1856</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;0.4191</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.4909</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.2135</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003c;0.0001</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.5435</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.0122</td></tr></tbody></table><table-wrap-foot><fn><p>The impact of baseline characteristics was analyzed using mixed models that account for repeated measurements and the random effect of subpopulations. All models incorporated the fixed effects of the post-vaccination week as a categorical variable, along with the variables shown in the table. The findings are presented in Sysmex units per mL (SU/mL). &#x003b2; represents the partial correlation coefficient. </p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="vaccines-12-01359-t003"><object-id pub-id-type="pii">vaccines-12-01359-t003_Table 3</object-id><label>Table 3</label><caption><p>Estimation of fixed effects on log-transformed anti-S1 IgG (BAU/mL).</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Males</th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">
</th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Females</th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">
</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td colspan="2" align="center" valign="middle" rowspan="1">Model 1</td><td colspan="2" align="center" valign="middle" rowspan="1">Model 2</td><td colspan="2" align="center" valign="middle" rowspan="1">Model 1</td><td colspan="2" align="center" valign="middle" rowspan="1">Model 2</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td colspan="2" align="center" valign="middle" rowspan="1">AIC = 258</td><td colspan="2" align="center" valign="middle" rowspan="1">AIC = 263</td><td colspan="2" align="center" valign="middle" rowspan="1">AIC = 529</td><td colspan="2" align="center" valign="middle" rowspan="1">AIC = 535</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td colspan="2" align="center" valign="middle" rowspan="1">162 observations</td><td colspan="2" align="center" valign="middle" rowspan="1">162 observations</td><td colspan="2" align="center" valign="middle" rowspan="1">255 observations</td><td colspan="2" align="center" valign="middle" rowspan="1">255 observations</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td colspan="2" align="center" valign="middle" rowspan="1">34 participants</td><td colspan="2" align="center" valign="middle" rowspan="1">34 participants</td><td colspan="2" align="center" valign="middle" rowspan="1">45 participants</td><td colspan="2" align="center" valign="middle" rowspan="1">45 participants</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Fixed effect</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x003b2;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x003b2;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x003b2;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x003b2;</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">p</italic>
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">BNT162b2(reference)</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">mRNA-1273</td><td align="center" valign="middle" rowspan="1" colspan="1">0.4599</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0062</td><td align="center" valign="middle" rowspan="1" colspan="1">0.3233</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0094</td><td align="center" valign="middle" rowspan="1" colspan="1">0.8347</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;0.0001</td><td align="center" valign="middle" rowspan="1" colspan="1">0.7555</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Age (per years of age)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.012</td><td align="center" valign="middle" rowspan="1" colspan="1">0.017</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.005</td><td align="center" valign="middle" rowspan="1" colspan="1">0.3195</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.005</td><td align="center" valign="middle" rowspan="1" colspan="1">0.1384</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.0038</td><td align="center" valign="middle" rowspan="1" colspan="1">0.4312</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Body height (per cm)</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.0165</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0659</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.002</td><td align="center" valign="middle" rowspan="1" colspan="1">0.8262</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Steroid use, yes</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.4357</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0455</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02014;</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Dyslipidemia, yes</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02014;</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02014;</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.6725</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0107</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Allergic disease, yes</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">0.1581</td><td align="center" valign="middle" rowspan="1" colspan="1">0.131</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.2301</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0196</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Exercise habit (per category)</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0388</td><td align="center" valign="middle" rowspan="1" colspan="1">0.46</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.0102</td><td align="center" valign="middle" rowspan="1" colspan="1">0.7973</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Cigarette smoke, yes</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;1.2462</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0064</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02014;</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02014;</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Ethanol intake (per category)</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.1627</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0487</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.0068</td><td align="center" valign="middle" rowspan="1" colspan="1">0.9326</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Perceived stress (per category)</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">0.07533</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0444</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">0.044</td><td align="center" valign="middle" rowspan="1" colspan="1">0.2769</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Sleep disturbance, yes</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.7196</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0246</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02212;0.388</td><td align="center" valign="middle" rowspan="1" colspan="1">0.064</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Log zinc (&#x003bc;g/dL)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;0.3268</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.3113</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02212;0.056</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.8676</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.609</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003c;0.0001</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.124</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.0131</td></tr></tbody></table><table-wrap-foot><fn><p>The influence of baseline characteristics was assessed using mixed models, which accounted for repeated measurements and the random effect of the subpopulation. Each model included post-vaccination week as a categorical fixed effect, along with the variables presented in the table. BAU (binding antibody units) were calibrated according to the WHO International Standard. &#x003b2; represents the partial correlation coefficient.</p></fn></table-wrap-foot></table-wrap></floats-group></article>